rs377022708 — ACAD9 Arg532Trp (R532W)

ACAD9 R532W — Riboflavin-Responsive Mitochondrial Complex I Failure

Inside every cell, the mitochondrial electron transport chain converts the chemical energy of nutrients into ATP — the universal cellular fuel. Complex I¹¹ Complex I
NADH:ubiquinone oxidoreductase, the largest of the five respiratory chain complexes, built from 44 protein subunits and assembled in a strictly ordered sequence is the entry point for electrons from NADH. Without functional complex I, tissues with the highest energy demands — heart muscle, skeletal muscle, and brain — fail first. ACAD9 is not itself a component of complex I, but it is one of the critical assembly factors required to build it: the protein physically interacts with NDUFAF1 and ECSIT to scaffold the assembly of complex I's proximal module, and its absence leaves the entire complex unassembled.

The R532W variant — a single cytosine-to-thymine substitution at nucleotide position 1,594 of the ACAD9 coding sequence — replaces the highly conserved arginine at protein position 532 with a bulky tryptophan residue. Protein structural modelling²² Protein structural modelling
Gerards M et al. Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain, 2011 shows that this substitution disrupts a stabilizing hydrogen bond within an α-helix of the ACAD9 protein, impairing the protein's ability to participate in complex I scaffolding. In the original family identified by Gerards et al., two siblings carried R532W in the homozygous state; a second unrelated patient carried R532W alongside a different ACAD9 mutation (compound heterozygous), confirming the allele is pathogenic in both configurations.

The Mechanism

ACAD9 belongs to the acyl-CoA dehydrogenase family and retains weak fatty acid oxidation enzymatic activity toward long-chain substrates, but its disease-causing role is firmly established as a complex I assembly factor. Nouws et al.³³ Nouws et al.
Nouws J et al. Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab, 2010 demonstrated that ACAD9 depletion by RNAi abolished complex I activity while leaving other respiratory chain complexes intact. ACAD9 assembles into an early intermediate complex during complex I biogenesis and is not a subunit of the final assembled complex — it acts transiently during construction, then is released.

The R532W substitution destabilizes the ACAD9 protein's tertiary structure, reducing both its FAD cofactor binding and its capacity to associate with NDUFAF1. Schiff et al.⁴⁴ Schiff et al.
Schiff M et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet, 2015 showed that both the assembly and the oxidation activities of ACAD9 contribute to disease severity, with the assembly function being the dominant determinant of phenotype. Importantly, ACAD9 requires FAD (derived from riboflavin, vitamin B2) as a cofactor — and this FAD dependence provides the mechanistic basis for riboflavin responsiveness: supplementing with high-dose riboflavin increases intracellular FAD, partially stabilizing the mutant ACAD9 protein and rescuing complex I assembly capacity.

The Evidence

The riboflavin responsiveness of ACAD9 deficiency is the most clinically actionable finding in this disorder. Gerards et al. 2011⁵⁵ Gerards et al. 2011
Gerards M et al. Brain, 2011 first demonstrated that high-dose riboflavin supplementation improved both complex I enzyme activity and clinical symptoms (exercise intolerance, lactic acidosis) in ACAD9-deficient patients. The largest subsequent cohort study, Repp et al. 2018⁶⁶ Repp et al. 2018
Repp BM et al. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis, 2018, recruited 70 ACAD9-deficient patients from European metabolic centers and found:

• Complex I activity improved in 9 of 15 patient-derived fibroblast lines (60%) following riboflavin supplementation in vitro
• Physicians reported a beneficial clinical effect in 20 of 31 treated patients (65%) for whom treatment data were available
• In patients with disease onset before age 1, riboflavin treatment was associated with statistically significant better survival (p = 5.34 × 10⁻⁵)

The same cohort documented the cardinal clinical features: cardiomyopathy in 85% (44/56 patients), muscular weakness in 75%, exercise intolerance in 72%, and elevated lactate as a near-universal biochemical marker. Severe intellectual disability was rare (1 patient), and over 70% of surviving patients maintained normal activities of daily living — underscoring that riboflavin response, when present, can dramatically improve prognosis.

An ACAD9 cardiac-specific knockout mouse model Sinsheimer et al. 2021⁷⁷ Sinsheimer et al. 2021
Sinsheimer A et al. Development and characterization of a mouse model for Acad9 deficiency. Mol Genet Metab, 2021 confirmed the primacy of complex I failure: knockout hearts lacked all supercomplexes and isolated complex I activity, with only complex II retained, reproducing the fatal neonatal cardiomyopathy seen in the most severely affected human patients.

Practical Actions

For individuals carrying two copies of the R532W allele (homozygous) or one copy paired with another ACAD9 pathogenic variant (compound heterozygous), the critical intervention is establishing care with a metabolic specialist and initiating high-dose riboflavin supplementation if not already underway. Cardiac monitoring is essential given the 85% prevalence of cardiomyopathy. Exercise-induced symptoms (muscle pain, weakness, dyspnea) should prompt immediate medical evaluation; lactic acid levels are a useful biomarker for disease monitoring and treatment response.

For heterozygous carriers, no symptoms are expected — ACAD9 deficiency is autosomal recessive and one functional copy is sufficient. The significance of carrier status is primarily reproductive.

Interactions

ACAD9 deficiency caused by R532W requires compound heterozygosity (R532W paired with a second pathogenic ACAD9 allele on the other chromosome) or homozygosity. The most commonly reported second alleles in the literature include R127Q (c.380G>A) and R469W (c.1405C>T), both identified in the original Gerards 2011 cohort. The Repp 2018 cohort identified 34 known and 18 novel variants — no biallelic loss-of-function (two null alleles) was identified in any patient, suggesting complete ACAD9 loss is incompatible with survival. The presence and nature of the second allele influences both phenotype severity and riboflavin responsiveness. Compound heterozygotes should have both alleles identified to guide prognosis.